These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
293 related articles for article (PubMed ID: 11772147)
1. Profiles of hepatic and dysrhythmic cardiovascular events following use of fluoroquinolone antibacterials: experience from large cohorts from the Drug Safety Research Unit Prescription-Event Monitoring database. Clark DW; Layton D; Wilton LV; Pearce GL; Shakir SA Drug Saf; 2001; 24(15):1143-54. PubMed ID: 11772147 [TBL] [Abstract][Full Text] [Related]
2. A comparison of ciprofloxacin, norfloxacin, ofloxacin, azithromycin and cefixime examined by observational cohort studies. Wilton LV; Pearce GL; Mann RD Br J Clin Pharmacol; 1996 Apr; 41(4):277-84. PubMed ID: 8730972 [TBL] [Abstract][Full Text] [Related]
3. Generating signals of drug-adverse effects from prescription databases and application to the risk of arrhythmia associated with antibacterials. Corrao G; Botteri E; Bagnardi V; Zambon A; Carobbio A; Falcone C; Leoni O Pharmacoepidemiol Drug Saf; 2005 Jan; 14(1):31-40. PubMed ID: 15390219 [TBL] [Abstract][Full Text] [Related]
4. In vitro phototoxic activities of new quinolone antibacterial agents: lipid peroxidative potentials. Fujita H; Matsuo I Photodermatol Photoimmunol Photomed; 1994 Oct; 10(5):202-5. PubMed ID: 7880759 [TBL] [Abstract][Full Text] [Related]
5. Frequency and expression of mutational resistance to the 4-quinolone antibacterials. Smith JT Scand J Infect Dis Suppl; 1986; 49():115-23. PubMed ID: 3547618 [TBL] [Abstract][Full Text] [Related]
6. Identification and evaluation of a possible signal of exacerbation of colitis during rofecoxib treatment, using Prescription-Event Monitoring data. Layton D; Heeley E; Shakir SA J Clin Pharm Ther; 2004 Apr; 29(2):171-81. PubMed ID: 15068407 [TBL] [Abstract][Full Text] [Related]
7. Comparison of the incidence rates of thromboembolic events reported for patients prescribed celecoxib and meloxicam in general practice in England using Prescription-Event Monitoring (PEM) data. Layton D; Hughes K; Harris S; Shakir SA Rheumatology (Oxford); 2003 Nov; 42(11):1354-64. PubMed ID: 12867585 [TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule. Wise R; Griggs D; Andrews JM Rev Infect Dis; 1988; 10 Suppl 1():S83-9. PubMed ID: 3162327 [TBL] [Abstract][Full Text] [Related]
9. Accumulation of new quinolones in the blood of elderly patients. Morita M; Hasuda A; Nakagawa H; Abe Y; Suzuki K J Int Med Res; 1993; 21(6):334-41. PubMed ID: 8143888 [TBL] [Abstract][Full Text] [Related]
10. Comparison of the incidence rates of thromboembolic events reported for patients prescribed rofecoxib and meloxicam in general practice in England using prescription-event monitoring (PEM) data. Layton D; Heeley E; Hughes K; Shakir SA Rheumatology (Oxford); 2003 Nov; 42(11):1342-53. PubMed ID: 12832706 [TBL] [Abstract][Full Text] [Related]
11. Quantitative comparison of the convulsive activity of combinations of twelve fluoroquinolones with five nonsteroidal antiinflammatory agents. Kim J; Ohtani H; Tsujimoto M; Sawada Y Drug Metab Pharmacokinet; 2009; 24(2):167-74. PubMed ID: 19430173 [TBL] [Abstract][Full Text] [Related]
12. The impact of norfloxacin, ciprofloxacin and ofloxacin on human gut colonization by Candida albicans. Mavromanolakis E; Maraki S; Cranidis A; Tselentis Y; Kontoyiannis DP; Samonis G Scand J Infect Dis; 2001; 33(6):477-8. PubMed ID: 11450873 [TBL] [Abstract][Full Text] [Related]
13. Association of oral ciprofloxacin, levofloxacin, ofloxacin and moxifloxacin with the risk of serious ventricular arrhythmia: a nationwide cohort study in Korea. Cho Y; Park HS BMJ Open; 2018 Sep; 8(9):e020974. PubMed ID: 30269062 [TBL] [Abstract][Full Text] [Related]
14. Comparison of the incidence rates of selected gastrointestinal events reported for patients prescribed celecoxib and meloxicam in general practice in England using prescription-event monitoring (PEM) data. Layton D; Hughes K; Harris S; Shakir SA Rheumatology (Oxford); 2003 Nov; 42(11):1332-41. PubMed ID: 12810929 [TBL] [Abstract][Full Text] [Related]
15. Postmarketing surveillance of quinolones, 1990 to 1992. Davey P; McDonald T Drugs; 1993; 45 Suppl 3():46-53. PubMed ID: 7689451 [TBL] [Abstract][Full Text] [Related]
16. Overview of the fluoroquinolone antibiotics. Just PM Pharmacotherapy; 1993; 13(2 Pt 2):4S-17S. PubMed ID: 8386356 [TBL] [Abstract][Full Text] [Related]
17. The comparative pharmacokinetics and tissue penetration of four quinolones including intravenously administered enoxacin. Wise R; Lister D; McNulty CA; Griggs D; Andrews JM Infection; 1986; 14 Suppl 3():S196-202. PubMed ID: 3463542 [TBL] [Abstract][Full Text] [Related]
18. Steady-state kinetics of the quinolone derivatives ofloxacin, enoxacin, ciprofloxacin and pefloxacin during maintenance treatment with theophylline. Wijnands WJ; Vree TB; Baars AM; van Herwaarden CL Drugs; 1987; 34 Suppl 1():159-69. PubMed ID: 3481317 [TBL] [Abstract][Full Text] [Related]
19. Relative risk of vaginal candidiasis after use of antibiotics compared with antidepressants in women: postmarketing surveillance data in England. Wilton L; Kollarova M; Heeley E; Shakir S Drug Saf; 2003; 26(8):589-97. PubMed ID: 12825971 [TBL] [Abstract][Full Text] [Related]
20. Safety profile of orlistat: results of a prescription-event monitoring study. Acharya NV; Wilton LV; Shakir SA Int J Obes (Lond); 2006 Nov; 30(11):1645-52. PubMed ID: 16552401 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]